Abstract: The present invention relates to a compound of formula I ##STR1## or a nontoxic pharmaceutically acceptable salt, physiologically hydrolyzable ester or solvate thereof, in whichX is --O--CO--, --NH--CO--, --CS--NH--, --CO--O--, --CO--NH--, --COS--, --SCO--, --SCH.sub.2 --, --CH.sub.2 --CH.sub.2 --, --C.tbd.C--, --CH.sub.2 --NH--, --COCH.sub.2 --, --NHCS--, --CH.sub.2 S--, --CH.sub.2 O--, --OCH.sub.2 --, --NHCH.sub.2 -- or --CR.sup.5 .dbd.CR.sup.6 --;R.sup.m and R.sup.k are independently hydrogen, halogen, C.sub.1-6 alkyl, hydroxy, C.sub.1-6 alkyloxy or nitro;n is zero or one;R.sup.4 is --(CH.sub.2).sub.t --Y, C.sub.1-6 alkyl, or C.sub.3-6 cycloalkyl;R.sup.1 is --CO.sub.2 Z, C.sub.1-6 alkyl, CH.sub.2 OH, --CONHR.sup.y, or CHO;R.sup.2 and R.sup.3 are independently hydrogen or C.sub.1-6 alkyl;R.sup.a and R.sup.b are independently hydrogen or C.sub.1-6 alkyl; but when n is one, R.sup.a and R.sup.

Abstract: This disclosure relates to a novel class of hydroxamic and carboxylic acid based matrix metalloproteinase inhibitor derivatives. The disclosure further relates to pharmaceutical compositions containing such compounds and to the use of such compounds and compositions in the treatment of matrix metalloproteinase induced diseases.

Abstract: Compounds of the formula ##STR1## wherein the symbols have the meaning described in the specification have retinoid-like biological activity.

Abstract: This invention relates to certain bicyclic compounds having a nucleus formed of two fused six membered rings, for example, isoquinoline, isoquinolone, tetrahydronaphthalene, dihydronaphthalene, or tetralone, substituted with both basic and acidic functionality, which are useful in inhibition of platelet aggregation.

Abstract: The invention relates to a compound selected from those of general formula (I): ##STR1## in which R, R.sub.1, R.sub.2 and R.sub.3 are as defined in the specification, an optical isomer, and an addition salt thereof with a pharmaceutically-acceptable base. Medicinal product which is useful in the treatment of disorders linked to abnormal melatonin activity.

Abstract: The present invention provides a method of preparing L-aspartyl-D-.alpha.-aminoalkane carboxylic acid-(S)-N-.alpha.-alkylbenzylamide which is less expensive and more efficient than previous methods using N-protected-L-aspartic anhydride.

Abstract: Disclosed are chiral hydrazine derivatives of the formula (Ia), (Ib), (Ic) and (Id) ##STR1## wherein: R.sup.1 and R.sup.2 are independently C.sub.1 -C.sub.10 alkyl;R.sup.3 is H or R.sup.4 wherein R.sup.4 is a hydroxy protecting group; andZ is H, --CHO, --C(O)OC(CH.sub.3).sub.3 or --C(O)OCH.sub.2 C.sub.6 H.sub.5.Also described is a process for preparing chiral hydrazines of the formula (Ia), (Ib), (Ic) and (Id).

Abstract: This invention relates to a process for hydrating olefins to the corresponding alcohols in the vapour phase in the presence of a catalyst system comprising a heteropolyacid catalyst supported on niobia. By using niobia as support, it is possible not only to increase the space-time-yield of the process but also to prolong the life of the support thereby reducing the frequency with which the support is changed or replaced on a plant. The process is particularly suited to producing ethanol from ethylene and isopropanol from propylene.

Abstract: Processes for the preparation of a metal salt of 3-mercapto-5-amino-(1H)-l,2,4-triazole or 3-mercapto-5-amino-(1H)-l,2,4-triazole, and a novel compound, sodium methyl N-cyanodithioiminocarbonate.

Abstract: Compound of formula (I): ##STR1## in which: R.sub.1 represents a hydroxyl, alkoxy or amino (unsubstituted or substituted) group,R.sub.2 represents an unsubstituted or substituted alkyl group,X.sub.1 represents --NH--,X.sub.2 represents --O--,R.sub.3 represents a hydrogen atom or an alkyl or phenyl group,R.sub.4 represents an alkyl group which is always substituted with one or more hydroxyl, benzyloxy, benzyloxycarbonylamino, amino, mono- or dialkylamino, acetoxy or 2,2-dimethyl-1,3-dioxolan-4-yl groups, such groups being identical or different,R.sub.5 represents a 3-indolylmethyl, naphthylmethyl, alkyl, phenyl or benzyl group, its isomers as well as its addition salts with a pharmaceutically acceptable acid or base, and medicinal products containing the same are useful as endothelin convertase inhibitor.

Abstract: The invention relates to the preparation of alkanesulphonic acids by photooxidation of sulphur-containing derivatives (thiols, sulphides, disulphides).The operation is carried out in solution in aqueous or alcoholic acetonitrile, with a light source irradiating between 200 and 400 nm.

Abstract: There is disclosed a process for producing a polyhydric alcohol which comprises reacting an aliphatic aldehyde with formaldehyde in the presence of a base compound consisting essentially of a hydrogencarbonate and a carbonate which have been formed by the oxidation or hydrolysis of a formic acid salt, in particular, the process according to the above process wherein a formic acid salt which has been by-produced by the reaction of an aliphatic aldehyde with formaldehyde is oxidized or hydrolyzed in the presence of a noble metal catalyst or a nickel catalyst in a reductive state to form a base compound consisting essentially of a hydrogencarbonate and a carbonate and this base compound is circulated through the reaction of the aldehyde and formaldehyde and is reused as the base compound. The above process enables easy and highly efficient production of high quality polyhydric alcohols substantially without by-producing a formic acid salt with a low value-added.

Abstract: A compound of the formula (I) or its pharmaceutically acceptable salt or ester: ##STR1## and intermediates thereof.

Abstract: Stabilisers of formula I ##STR1## wherein R.sub.1 and R.sub.2 may be C.sub.1 -C.sub.5 alkyl, the substituents R.sub.3 to R.sub.8 may be hydrogen, the variable n may be 1 or 2, and, when n is 1, A may be an alkoxy radical, and, when n is 2, A may be a diamine radical.

Abstract: Provided is a compound of the formula: ##STR1## This compound is an intermediate to and is used for preparing the arthropodicidal oxidiazine Compound II described in the specification.

Abstract: Improved catalysts for isomerizing epoxides to allylic alcohols are disclosed. The catalysts contain lithium phosphate supported on high-purity silica. The use of high-purity silica as a support results in improved epoxide conversion and allylic alcohol selectivity, and reduced by-product generation. The invention includes a process for isomerizing epoxides using the catalysts. The process is well-suited to the manufacture of allyl alcohol from propylene oxide.

Abstract: The invention provides novel N-acyloxyalkyl-carboxamides of the general formula (I): ##STR1## in which R.sup.1 is alkyl, alkenyl, alkinyl, cycloalkyl, cycloalkylalkyl, arylalkyl or heteroarylalkyl, each of which is optionally substituted,R.sup.2 is optionally substituted alkyl andR.sup.3 is hydrogen, halogen or optionally substituted alkyl,in the isolated and pure form, and a process for their preparation.

Abstract: The invention is a process for hydroformylating multicomponent syngas feed streams containing CO, H.sub.2, C.sub.2 to C.sub.5 olefins and mixtures thereof and C.sub.2 to C.sub.5 alkynes and mixtures thereof by contacting the multicomponent syngas feed stream with a solution of an oil soluble rhodium complex catalyst produced by complexing in solution a low valence Rh and an oil soluble triorganophoshorous compound wherein the catalyst has a P/Rh ratio of at least 30, a concentration of Rh in solution from about 1 to about 1000 ppm by weight, a total concentration of coordinatively active P of at least about 0.01 mol/l, and a ratio of [P]/p.sub.co of at least 0.1 mmol/l/kPa, wherein [P] is the total concentration of coordinatively active phosphorous in the solution, and p.sub.co is the partial pressure of CO, to produce the corresponding C.sub.3 to C.sub.6 aldehydes. The process has utility for the hydroformylation of streams that contain olefins and alkynes.

Abstract: Compounds of the formula (I): Ar.sub.1 --CH(OH)--CH.sub.2 --NH--CH.sub.2 --X--CH.sub.2 --E--(CH.sub.2).sub.n --Y--Ar.sub.2, in which the substituents and symbols have the meanings given in the description, are novel active compounds having, in particular, a broncholytic action.

Abstract: Compounds and methods are disclosed that are useful in inhibiting the TNF-.alpha. converting enzyme (TACE) responsible for cleavage of TNF-.alpha. precursor to provide biologically active TNF-.alpha.. The compounds employed in the invention are peptidyl derivatives having active groups capable of inhibiting TACE such as, hydroxamates, thiols, phosphoryls and carboxyls.